S Kravcik
Overview
Explore the profile of S Kravcik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Campbell R, Chow B, Victor G, Kravcik S, Hodge W
Can J Infect Dis
. 2007 Dec;
12(5):300-4.
PMID: 18159353
Objective: To describe the course and outcome of cytomegalovirus (CMV) retinitis among AIDS patients treated with intravitreal ganciclovir and systemic highly active antiretroviral therapy (HAART). The secondary objective was to...
2.
Proulx N, Frechette D, Toye B, Chan J, Kravcik S
QJM
. 2005 Mar;
98(4):291-8.
PMID: 15760921
Background: Bacterial meningitis continues to cause high mortality. Few studies address the possible association between this mortality and antibiotic administration delays. Aim: To determine whether delays in antibiotic administration are...
3.
Kravcik S, Magill A, Sanghvi B, Ogden R, Cameron W, Lewis R, et al.
HIV Clin Trials
. 2001 Oct;
2(2):160-70.
PMID: 11590524
Background: Therapy of HIV infection with protease inhibitors (PIs) may be associated with improvements in CD4 T-cell number via a mechanism that is independent of effects on plasma viral load...
4.
Kravcik S
HIV Clin Trials
. 2001 Oct;
1(3):37-50.
PMID: 11590504
The dramatic clinical benefit of highly active antiretroviral therapy has been offset, to an extent, by the development of unforeseen long-term toxicities. Of these, the HIV lipodystrophy syndrome is most...
5.
Kravcik S
Expert Opin Pharmacother
. 2001 May;
2(2):303-15.
PMID: 11336588
Saquinavir is a peptidomimetic inhibitor of HIV protease. Initially marketed as Invirasetrade mark, the effectiveness of saquinavir was greatly hindered by its nearly complete first pass metabolism by cytochrome P450...
6.
Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron D
Clin Pharmacol Ther
. 2001 Feb;
68(6):637-46.
PMID: 11180024
Aim: Our aim was to evaluate the effect of ketoconazole on ritonavir and saquinavir plasma and cerebrospinal fluid (CSF) concentrations. Methods: Twelve patients who were human immunodeficiency virus-seropositive and who...
7.
Angel J, Parato K, Kumar A, Kravcik S, Badley A, Fex C, et al.
J Infect Dis
. 2001 Feb;
183(4):546-54.
PMID: 11170979
The degree of immune recovery achievable with anti-human immunodeficiency virus (HIV) therapy remains to be established. The effects of potent antiretroviral therapy, including ritonavir and saquinavir, on immune function were...
8.
Chan J, Kravcik S, Angel J
J Acquir Immune Defic Syndr
. 2000 Jun;
22(2):209-10.
PMID: 10843538
No abstract available.
9.
Phenix B, Angel J, Mandy F, Kravcik S, Parato K, Chambers K, et al.
AIDS Res Hum Retroviruses
. 2000 Apr;
16(6):559-67.
PMID: 10777146
Antiretroviral treatment of patients infected with HIV results in improvements in CD4+ T cell number. Emerging evidence suggests that some of the improvements in CD4+ T cell number that occur...
10.
Kravcik S, Victor G, Angel J, Badley A, Garber G, Cameron D
Clin Infect Dis
. 1999 Oct;
29(3):702-3.
PMID: 10530484
No abstract available.